Co-Authors
This is a "connection" page, showing publications co-authored by Silvio Danese and Antonino Spinelli.
Connection Strength
4.295
-
Author Correction: Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020 May 06.
Score: 0.881
-
Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020 05; 17(5):253-255.
Score: 0.880
-
Author response to: Covid-19-related pancreatic injury. Br J Surg. 2020 06; 107(7):e191.
Score: 0.880
-
Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. J Crohns Colitis. 2020 Sep 16; 14(9):1330-1333.
Score: 0.226
-
Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. Drugs Today (Barc). 2019 Feb; 55(2):95-105.
Score: 0.202
-
Are Surgical Rates Decreasing in the Biological Era In IBD? Curr Drug Targets. 2019; 20(13):1356-1362.
Score: 0.201
-
The impact of biologics in surgical outcomes in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:79-87.
Score: 0.193
-
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
Score: 0.183
-
MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. Gastroenterology. 2017 11; 153(5):1363-1377.e6.
Score: 0.182
-
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Dig Liver Dis. 2017 Aug; 49(8):872-877.
Score: 0.178
-
Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. J Crohns Colitis. 2015 Jul; 9(7):541-7.
Score: 0.155
-
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. Cancer Res. 2019 08 15; 79(16):4196-4210.
Score: 0.052
-
Surgical rates in the era of biological therapy: up, down or unchanged? Curr Opin Gastroenterol. 2017 Jul; 33(4):246-253.
Score: 0.045
-
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. United European Gastroenterol J. 2016 Dec; 4(6):784-793.
Score: 0.040